Trial Outcomes & Findings for Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation (NCT NCT02553538)

NCT ID: NCT02553538

Last Updated: 2018-03-26

Results Overview

The primary outcome was the overall cancer screening test completion rate over the follow-up period for each eligible patient, with all eligible cancers combined in intention to treat analyses. For example, a patient who was eligible for a total of 3 screening tests at a given time could have a completion rate of 0% (none of the 3 tests completed) 33%, 67%, or 100% (all 3 tests completed). By assessing each patient's completion rate over the 8-month follow-up period, the average completion rate over time was estimated from the area under the curve. We also calculated the completion rate for each individual cancer as the percentage of time screening was up to date among eligible patients during follow-up.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1612 participants

Primary outcome timeframe

8 months

Results posted on

2018-03-26

Participant Flow

Participant milestones

Participant milestones
Measure
Patient Navigation Intervention
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Overall Study
STARTED
792
820
Overall Study
COMPLETED
605
764
Overall Study
NOT COMPLETED
187
56

Reasons for withdrawal

Reasons for withdrawal
Measure
Patient Navigation Intervention
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Overall Study
Could Not Reach by Telephone
133
0
Overall Study
Died or Left Network
54
56

Baseline Characteristics

Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patient Navigation Intervention
n=792 Participants
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
n=820 Participants
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Total
n=1612 Participants
Total of all reporting groups
Age, Continuous
56.9 years
STANDARD_DEVIATION 9.3 • n=5 Participants
57.1 years
STANDARD_DEVIATION 9.4 • n=7 Participants
57.0 years
STANDARD_DEVIATION 9.35 • n=5 Participants
Sex: Female, Male
Female
479 Participants
n=5 Participants
496 Participants
n=7 Participants
975 Participants
n=5 Participants
Sex: Female, Male
Male
313 Participants
n=5 Participants
324 Participants
n=7 Participants
637 Participants
n=5 Participants
Race
Asian
61 participants
n=5 Participants
82 participants
n=7 Participants
143 participants
n=5 Participants
Race
Black
94 participants
n=5 Participants
83 participants
n=7 Participants
177 participants
n=5 Participants
Race
Hispanic
104 participants
n=5 Participants
71 participants
n=7 Participants
175 participants
n=5 Participants
Race
Other/Unknown
44 participants
n=5 Participants
42 participants
n=7 Participants
86 participants
n=5 Participants
Race
White
489 participants
n=5 Participants
542 participants
n=7 Participants
1031 participants
n=5 Participants
Language
English
565 participants
n=5 Participants
608 participants
n=7 Participants
1173 participants
n=5 Participants
Language
Not English
227 participants
n=5 Participants
212 participants
n=7 Participants
439 participants
n=5 Participants
Insurance
Commercial
430 participants
n=5 Participants
410 participants
n=7 Participants
840 participants
n=5 Participants
Insurance
Medicaid
174 participants
n=5 Participants
200 participants
n=7 Participants
374 participants
n=5 Participants
Insurance
Medicare
147 participants
n=5 Participants
169 participants
n=7 Participants
316 participants
n=5 Participants
Insurance
Self-Pay
41 participants
n=5 Participants
41 participants
n=7 Participants
82 participants
n=5 Participants
Patient-Physician Connectedness Status
Physician-connected
670 participants
n=5 Participants
674 participants
n=7 Participants
1344 participants
n=5 Participants
Patient-Physician Connectedness Status
Practice-connected
122 participants
n=5 Participants
146 participants
n=7 Participants
268 participants
n=5 Participants
Clinic Visits in Prior 3-Year
6.9 visits
STANDARD_DEVIATION 7.0 • n=5 Participants
6.8 visits
STANDARD_DEVIATION 6.5 • n=7 Participants
6.85 visits
STANDARD_DEVIATION 6.75 • n=5 Participants

PRIMARY outcome

Timeframe: 8 months

The primary outcome was the overall cancer screening test completion rate over the follow-up period for each eligible patient, with all eligible cancers combined in intention to treat analyses. For example, a patient who was eligible for a total of 3 screening tests at a given time could have a completion rate of 0% (none of the 3 tests completed) 33%, 67%, or 100% (all 3 tests completed). By assessing each patient's completion rate over the 8-month follow-up period, the average completion rate over time was estimated from the area under the curve. We also calculated the completion rate for each individual cancer as the percentage of time screening was up to date among eligible patients during follow-up.

Outcome measures

Outcome measures
Measure
Patient Navigation Intervention
n=792 Participants
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
n=820 Participants
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Percentage of Cancer Screening Tests Completed - Intention to Treat
All Cancers Combined
10.2 percentage of screening visits completed
Interval 8.7 to 11.7
6.8 percentage of screening visits completed
Interval 5.5 to 8.1
Percentage of Cancer Screening Tests Completed - Intention to Treat
Breast
14.7 percentage of screening visits completed
Interval 12.0 to 17.4
11.0 percentage of screening visits completed
Interval 8.5 to 13.4
Percentage of Cancer Screening Tests Completed - Intention to Treat
Cervical
11.1 percentage of screening visits completed
Interval 8.4 to 13.9
5.7 percentage of screening visits completed
Interval 3.7 to 7.7
Percentage of Cancer Screening Tests Completed - Intention to Treat
Colorectal
7.6 percentage of screening visits completed
Interval 5.9 to 9.2
4.6 percentage of screening visits completed
Interval 3.2 to 5.9

PRIMARY outcome

Timeframe: 8 Months

The primary outcome was the average cancer screening test completion rate over the follow-up period for each eligible patient, with all eligible cancers combined in as treated analyses - excluding patients who either left the network or died during follow-up. The cancer screening test completion rate for each subject was calculated daily, then averaged across the 8-month study period. On any given day, the screening test completion rate was calculated as the number of tests completed divided by the number of eligible tests.

Outcome measures

Outcome measures
Measure
Patient Navigation Intervention
n=605 Participants
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
n=764 Participants
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Percentage of Cancer Screening Tests Completed - As Treated
All Cancers Combined
13.1 percentage of completed screening visits
Interval 11.8 to 15.6
7.2 percentage of completed screening visits
Interval 5.9 to 8.6
Percentage of Cancer Screening Tests Completed - As Treated
Breast
18.8 percentage of completed screening visits
Interval 15.6 to 22.4
11.7 percentage of completed screening visits
Interval 9.0 to 14.3
Percentage of Cancer Screening Tests Completed - As Treated
Cervical
14.1 percentage of completed screening visits
Interval 11.0 to 18.2
6.2 percentage of completed screening visits
Interval 4.0 to 8.3
Percentage of Cancer Screening Tests Completed - As Treated
Colorectal
9.9 percentage of completed screening visits
Interval 8.0 to 12.3
4.9 percentage of completed screening visits
Interval 3.4 to 6.3

SECONDARY outcome

Timeframe: 8 Months

The percentage of patients completing any cancer screening during follow-up among those who were eligible and overdue for at least one cancer screening at baseline in intention to treat analyses, as the percentage of patients completing each type of cancer screening among those who were eligible and overdue at baseline in intention to treat analyses.

Outcome measures

Outcome measures
Measure
Patient Navigation Intervention
n=792 Participants
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
n=820 Participants
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Percentage of Patients Completing Any Cancer Screening Test (Intention to Treat)
Any Screening
25.5 percentage of patients
17.0 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (Intention to Treat)
Breast
23.4 percentage of patients
16.6 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (Intention to Treat)
Cervical
14.4 percentage of patients
8.6 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (Intention to Treat)
Colorectal
13.7 percentage of patients
7.0 percentage of patients

SECONDARY outcome

Timeframe: 8 Months

The percentage of patients completing any cancer screening during follow-up among those who were eligible and overdue for at least one cancer screening at baseline in intention to treat analyses, as the percentage of patients completing each type of cancer screening among those who were eligible and overdue at baseline, removing patients who left our primary care network or who died during follow-up from both intervention and control arms, and also removed patients the navigators were not able to contact from the intervention arm.

Outcome measures

Outcome measures
Measure
Patient Navigation Intervention
n=605 Participants
Patients randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Standard of Care - No Intervention
n=764 Participants
Patients randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the patient a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
Percentage of Patients Completing Any Cancer Screening Test (As Treated)
Breast
29.6 percentage of patients
17.6 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (As Treated)
Any Screening
32.9 percentage of patients
18.1 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (As Treated)
Cervical
18.0 percentage of patients
9.3 percentage of patients
Percentage of Patients Completing Any Cancer Screening Test (As Treated)
Colorectal
18.1 percentage of patients
7.6 percentage of patients

Adverse Events

Patient Navigation Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard of Care - No Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Sanja Percac-Lima

Massachusetts General Hospital

Phone: 617-643-6980

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place